$0.26
6.16% today
Nasdaq, Dec 19, 10:11 pm CET
ISIN
US00972G1085
Symbol
AKTX

Akari Therapeutics Plc Sponsored ADR Stock price

$0.25
-0.29 53.83% 1M
-0.91 78.70% 6M
-0.98 79.92% YTD
-0.72 74.48% 1Y
-7.96 97.01% 3Y
-39.36 99.38% 5Y
-334.16 99.93% 10Y
-3,999.76 99.99% 20Y
Nasdaq, Closing price Thu, Dec 18 2025
-0.01 2.20%
ISIN
US00972G1085
Symbol
AKTX
Industry

Key metrics

Basic
Market capitalization
$8.2m
Enterprise Value
$7.8m
Net debt
positive
Cash
$2.5m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.4
Financial Health
Equity Ratio
44.0%
Return on Equity
-89.0%
ROCE
-44.2%
ROIC
-39.6%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-13.2m | -
EBIT
$-13.2m | $-13.2m
Net Income
$-15.8m | -
Free Cash Flow
$-9.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
56.4% | -
EBIT
56.4% | 20.8%
Net Income
39.4% | -
Free Cash Flow
44.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
-
Short interest
0.7%
Employees
9
Rev per Employee
$0.0
Show more

Is Akari Therapeutics Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Akari Therapeutics Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:

Buy
89%
Hold
11%

Financial data from Akari Therapeutics Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
46% 46%
-
- Research and Development Expense 2.98 2.98
73% 73%
-
-13 -13
56% 56%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
56% 56%
-
Net Profit -16 -16
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akari Therapeutics Plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akari Therapeutics Plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
one day ago
Watch the “What This Means” video here
Neutral
GlobeNewsWire
3 days ago
New cash portion of offering includes >20% participation from Directors, Officers and Executive Management New cash portion of offering includes >20% participation from Directors, Officers and Executive Management
Neutral
GlobeNewsWire
10 days ago
Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates
More Akari Therapeutics Plc Sponsored ADR News

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Abizer Gaslightwala
Employees 9
Founded 2004
Website www.akaritx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today